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The transcription factor STAT1 is important in natural
killer (NK) cells, which provide immediate defense
against tumor and virally infected cells. We show
that mutation of a single phosphorylation site
(Stat1-S727A) enhances NK cell cytotoxicity against
a range of tumor cells, accompanied by increased
expression of perforin and granzyme B. Stat1-
S727A mice display significantly delayed disease
onset in NK cell-surveilled tumor models including
melanoma, leukemia, and metastasizing breast can-
cer. Constitutive phosphorylation of S727 depends
on cyclin-dependent kinase 8 (CDK8). Inhibition of
CDK8-mediated STAT1-S727 phosphorylation may
thus represent a therapeutic strategy for stimulating
NK cell-mediated tumor surveillance.INTRODUCTION
Signal transducer and activator of transcription 1 (STAT1) is acti-
vated downstream of interferons (IFNs) and transmits antiviral
and antimicrobial signals from the cell surface to the nucleus
(Stark and Darnell, 2012). Mice with complete or tissue-specific
loss of Stat1 are prone to succumb to infections and to develop
tumors (Kaplan et al., 1998; Klover et al., 2010; Schneckenleith-
ner et al., 2011; Koromilas and Sexl, 2013). STAT1 activity is
regulated posttranscriptionally, e.g., by JAK-mediated phos-
phorylation of tyrosine701 (Y701), which allows STAT1 dimeriza-
tion and nuclear translocation. Various kinases phosphorylate
STAT1’s transactivation domain at serine727 (S727) (Kovarik
et al., 1999; Nair et al., 2002; Deb et al., 2003; Bancerek et al.,
2013). IFN-induced S727 phosphorylation occurs after STAT1dimers bind to DNA (Sadzak et al., 2008) and modulates tran-
scription (Wen et al., 1995). Knockin mice with point-mutated
STAT1-S727 (Stat1-S727A) display reduced antimicrobial acti-
vity, emphasizing the importance of the phosphorylation site
and suggesting that the S727A mutation generates a hypomor-
phic Stat1 allele (Varinou et al., 2003; Pilz et al., 2009).
Natural killer (NK) cells are important in the defense against
virally infectedandmalignant cells (Vivier et al., 2011). Their devel-
opment, activation, andcytotoxic function are tightly regulatedby
cytokines, which induce the JAK/STAT signaling pathway. Inter-
leukins 2 and 15 (IL-2 and IL-15) drive NK cell development, pro-
liferation, and homeostasis and signal predominantly via STAT5
(Lodolceet al., 1998). STAT1,STAT3, andSTAT4aredownstream
of IL-12, mediating NK cell activation and cytotoxicity and trig-
gering the transcription of IFN-g, granzymes, and perforin (Wat-
ford et al., 2004). IFN type I induces NK cell cytotoxicity in viral
infections and stimulates NK cell proliferation and survival via
activation of dendritic cells (DCs) (Nguyen et al., 2002; Lucas
et al., 2007).
Although STAT1 regulates many aspects of NK cell biology
(Lee et al., 2000; Kovacic et al., 2006), the role of STAT1-S727
phosphorylation in NK cells is unknown. We show that in
Stat1-S727A mutant mice, NK cells display higher cytotoxicity
toward a broad panel of target cells, leading to more efficient
tumor clearance. The upstream kinase is CDK8, which offers a
therapeutic opportunity to stimulate NK cell activity.
RESULTS
High Cytotoxic Activity of Stat1-S727A NK Cells
Stat1-S727A mice exhibit slightly elevated numbers of mature
NK cells (mNKs) in bone marrow, spleen, and blood (Figures 1A
and 1B) not paralleled by enhanced numbers of NK cell
precursors (Figure 1A) nor by increased proliferation (data not
shown). Unlike the situation in Stat1/ NK cells, maturation ofCell Reports 4, 437–444, August 15, 2013 ª2013 The Authors 437
BA
DC
FE
HG
Spleen
0
2
4
6
8
10
C
D
3-
D
X5
+ N
K
p4
6+
(%
 o
f l
ym
ph
oc
yt
es
) * *
Blood
0
5
10
15
20 * +/+
S727A
-/-
RMA
10
:1 5:1 2.5
:1
E:T ratio
C
ou
nt
s
KLRG1 NKG2A/C/E
36±2%
24±2%
8±2%
32±3%
45±3%
56±2%
+/+          S727A         -/- Isotype+/+ S727A -/-
C
D
27
CD11b
YAC-1
%
 s
pe
ci
fic
 ly
si
s
20
:1
10
:1 5:1
0
20
40
60
80
***
*
RMA-Rae1
10
:1 5:1 2.5
:1
*
*
***
+/+
S727A
RMA-S
10
:1 5:1 2.5
:1
*
*
*
E:T ratio
IgG
%
 s
pe
ci
fic
 ly
si
s
20
:1
10
:1 5:1
0
10
20
30
aLy49D
20
:1
10
:1 5:1
+/+
S727A
**
**
a2B4
20
:1
10
:1 5:1
*
*
aNK1.1
20
:1
10
:1 5:1
* *
**
# iNKs # mNKs
** * +/+
S727A
-/-
    # NKPs
0
2000
4000
6000
8000
10000
pe
r 1
*1
06
 B
M
 c
el
ls
C
ou
nt
s
Perforin
IL-2
+PMA
+iono
+/+
S727A   
-/-
Isotype
G
ra
nz
ym
e
B
IFN-γ
ex
vivo
+IL-2+IL-12
+/+                        S727A                     -/-
Figure 1. Presence, Development, and Cytotoxic Function of Stat1-S727A NK Cells
(A) Bone marrow was investigated for NK cell precursors (NKPs, CD3Ter-119GR1B220CD122+NK1.1DX5), immature NK cells (iNKs, CD3Ter-
119GR1B220CD122+NK1.1+DX5), and mNKs (CD3Ter-119GR1B220CD122+NK1.1+DX5+). Each symbol represents an individual mouse; small hor-
izontal lines indicate the mean (*p < 0.05, **p < 0.01; one-way ANOVA and Tukey’s post hoc test).
(B) Number of CD3DX5+NKp46+ NK cells, given as percentages of spleen and blood lymphocytes, is shown. Each symbol represents an individual mouse;
horizontal lines indicate the mean (*p < 0.05; one-way ANOVA and Tukey’s post hoc test).
(C) NK cell maturation profiles represented by the expression of CD27 andCD11b onCD3NK1.1+ splenocytes are shown. Data are representative for at least five
independent experiments with n > 10 for each genotype.
(D) Expression of KLRG1 andNKG2A/C/E onCD3DX5+NK1.1+NKp46+ splenocytes is shown. Numbers indicate the percentage of gate+ (horizontal line) NK cells
± SEM; nR 9 for each genotype.
(E) Cytotoxicity of wild-type versus Stat1-S727A NK cells against YAC-1, RMA, RMA-S, and RMA-Rae1 tumor targets at given effector-to-target (E:T) ratios,
measured in a 4 hr [51Cr]-release cytotoxicity assay is shown. Symbols represent means, and error bars indicate SEM of triplicates (*p < 0.05, ***p < 0.001;
unpaired t test). Data are representative of three independent experiments.
(F) R-ADCC against FcR+ Daudi target cells crosslinked with antibodies against NK1.1, 2B4, and Ly49D is shown. Symbols represent means, and error bars
indicate SEM of triplicates (*p < 0.05, **p < 0.01; unpaired t test). Data are representative of two independent experiments.
(G) IFN-g and granzyme B protein expression in splenic NK cells (gated on CD3NKp46+) ex vivo and after 4 hr stimulation with IL-2 and IL-12 is presented.
(H) LAK cells stained intracellularly for perforin under normal culturing conditions and after 4 hr treatment with PMA and ionomycin are shown.
See also Figure S1 and Table S1.
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Stat1-S727A NK cells is unaffected (Figure 1C). Consistent with
previous findings by Robbins et al. (2005), Stat1/ peripheral
NK cells have an immature phenotype (Figures 1C and 1D; Table
S1). In contrast, changesonStat1-S727A cells areminor: only the
relative increase of NKG2A/C/E+ and a reduction of KLRG1+ NK
cells (Figure 1D; Table S1) are consistently observed despite
normal levels of MHC class I (data not shown).
Unexpectedly, purified and in vitro-expanded NK cells derived
from Stat1-S727A mice show significantly higher cytotoxicity
toward YAC-1, RMA-S, and RMA-Rae1 target cells (Figure 1E).
Redirected antibody-dependent cellular cytotoxicity (R-ADCC)
against the receptors NK1.1, 2B4, and Ly49D confirmed this
finding (Figure 1F).
IL-12 is a potent activator of NK cell cytotoxicity and induces
the transcription of granzymes, perforin, and IFN-g (Watford
et al., 2004; Figure S1). Il12p40 expression is enhanced in
Stat1-S727A bone marrow-derived macrophages upon CpG
treatment (Schroder et al., 2007). We failed to detect any differ-
ences in Il12p40 expression under basal conditions. Stimulation
with LPS increased Il12p40 expression in Stat1-S727A spleno-
cytes less than in wild-type cells (Figure S2), showing that
enhanced NK cell cytotoxicity in Stat1-S727Amice is not caused
by higher IL-12 levels. IL-12-dependent STAT activation is com-
parable in wild-type and Stat1-S727A NK cells (Figures 2 and
S2). Surprisingly, we found reduced IFN-g production upon IL-
12 stimulation in Stat1/ and Stat1-S727A NK cells (Figures
1G and S1): Stat1-S727A mutation can thus phenocopy some
aspects of Stat1 deficiency. In contrast, granzyme B expression
is significantly enhanced in primary Stat1-S727A NK cells, both
without and after stimulation by IL-2 and IL-12 (Figure 1G).
Levels of perforin are enhanced under standard culturing condi-
tions and especially after stimulation with PMA and ionomycin
(Figure 1H). The increased amounts of granzyme B and perforin
correlate with changes in the levels of microRNA-378 and -30e,
which posttranscriptionally regulate the two enzymes, respec-
tively (Wang et al., 2012) (see Extended Results; Figure S1).
Constitutive Basal Phosphorylation on STAT1-S727 Is
Mediated by CDK8
In contrast to Y701, S727 is constitutively phosphorylated in
unstimulated wild-type NK cells (Figures 2A–2C). In lympho-
kine-activated killer (LAK) cells, STAT1-S727 phosphorylation
is enhanced by IFN-b or IL-12 (Figures 2B and 2C). In line with
previous reports by Bromberg et al. (1996) and Horvath and
Darnell (1996), lack of S727 phosphorylation does not interfere
with IFN-b-mediated transcription of typical STAT1 target genes
(Figure S2).
Web-based inquiries to identify the STAT1-S727 kinase gave
the highest support vector machine (SVM) scores for cyclin-
dependent kinases (CDKs) and mitogen-activated protein
kinases (MAPKs). The pan-CDK inhibitor flavopiridol strongly
reduces STAT1-S727 phosphorylation, whereas roscovitine,
which inhibits CDK1, CDK2, CDK5, CDK7, and CDK9, has no
impact. Similarly, the p38 MAPK inhibitor BIRB 0796 reduces
STAT1-S727 phosphorylation, but the prototypic p38 inhibitor
SB 203580 does not (Figure 2D). We performed knockdown of
CDK8, a kinase targeted by both flavopiridol and BIRB 0796
(Davis et al., 2011), in primary NK cells and found a reductionof STAT1-S727 phosphorylation (Figure 2E). The lifespan of pri-
mary NK cells is limited, so we generated immortalized primary
murine NK cells from mice with a disrupted Ink4a tumor sup-
pressor locus (Serrano et al., 1996). The immortalized NK cells
retain their growth dependence on IL-2 and their functionality
with respect to IFN-g production and cytotoxicity for several
months (Figure S2). CDK8 knockdown in the Ink4a/ NK cells
verified the link between CDK8, STAT1-S727 phosphorylation
and enhanced cytotoxicity (Figures 2F and 2G). Attempts to
inhibit CDK8 in primary NK cells and to test the resulting cytotox-
icity were inconclusive because there is still no inhibitor specific
for CDK8. Inhibitors target multiple kinases, and this renders an
interpretation of the assays impossible.
Stat1-S727A Mice Are Less Susceptible to NK Cell-
Surveilled Tumors
To examine whether the increased cell-mediated cytotoxicity
associated with the Stat1-S727A mutation confers enhanced
protection against NK cell-surveilled tumors, we used B16F10
melanoma cells, which form tumor nodules in the lung upon
intravenous injection. In Stat1/ animals, the first nodules
were detected as early as 7 days postinjection. Wild-type ani-
mals showed the first tumors after 14 days, whereas Stat1-
S727A mice remained free of visible tumor nodules until day 21
(Figures 3A and 3B). The enhanced resistance of Stat1-S727A
mice to B16F10 tumor formation led to a significant increase in
overall survival (Figure 3C).
We also injected wild-type, Stat1/, and Stat1-S727A mice
intravenously with v-abl-transformed leukemic cells, which are
eradicated by NK cells (Stoiber et al., 2004). Stat1/ mice
rapidly succumb to leukemia, but Stat1-S727A animals are
significantly less susceptible (Figure 3D). As a control, we used
Rag2//Stat1-S727A mice that lack B and T lymphocytes (Fig-
ure 3E). The survival curves of Rag2/ and Rag2//Stat1-
S727A mice are superimposable with those of wild-type and
Stat1-S727A mice. Disease severity at the day of sacrifice was
comparable (Figure S3).
Metastasis represents a major problem in cancer therapy.
In the 4T1-induced cancer model, the growth of the primary
breast tumor is NK cell independent, whereas its ability to
metastasize is restricted by NK cell-mediated tumor surveil-
lance. Wild-type mice, Stat1/ mice, and mice with the Stat1-
S727A mutation showed no differences in volume or weight of
primary tumors (Figures 4A and 4B). We also monitored white
blood cell (WBC) counts and the appearance of myeloid-derived
suppressor cells (MDSCs, defined as GR1+CD11b+) in the
blood, surrogate markers of disease severity. Despite compara-
ble growth rates of the primary tumors, WBC and MDSC counts
were significantly enhanced in Stat1/ mice from day 21. After
31 days, WBC and MDSC counts markedly increased in wild-
type mice but stayed clearly lower in Stat1-S727Amice (Figures
4C and 4D). The lungs of all diseased mice were investigated for
metastatic infiltrates. As expected, Stat1/ mice had dense tu-
mor cell infiltration in their lungs. At day 31 postinoculation, wild-
type animals had significantly enhanced lung weights and
severe metastatic burden, whereas Stat1-S727A mice were
completely metastasis-free (Figures 4E–4G). To confirm the
impact of NK cell-mediated tumor surveillance of 4T1Cell Reports 4, 437–444, August 15, 2013 ª2013 The Authors 439
Figure 2. Constitutive Basal STAT1-S727 Phosphorylation in NK Cells Is Mediated by CDK8
(A) Western blot of freshly isolated DX5+ splenocytes from wild-type animals shows constitutive basal phosphorylation on STAT1-S727 in vivo.
(B andC) In vitro-expanded LAK cells fromwild-type andStat1-S727Amicewere treatedwith orwithout (B) 100 U/ml IFN-b or (C) 5 ng/ml IL-12 for the given times,
and the phosphorylation on STAT1-Y701 and STAT1-S727 was investigated by western blot. Stat1/ LAK cells served as negative control and HSC-70 as
loading control.
(D) Wild-type LAK cells were treated with different kinase inhibitors targeting CDKs (roscovitine and flavopiridol) or MAPK p38 (BIRB 0796 and SB 203580), and
the phosphorylation status of STAT1-S727 was determined in a western blot.
(E) CDK8 knockdown in primary NK cells with two hairpins led to reduced STAT1-S727 phosphorylation. A random hairpin served as control.
(legend continued on next page)
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Figure 3. Stat1-S727A Mice Are Less Susceptible to B16F10 Melanoma and v-abl+ Leukemic Cells
(A) Wild-type, Stat1-S727A, and Stat1/mice were injected intravenously with B16F10 melanoma cells. At the indicated time points, mice were sacrificed, and
tumor nodules visible on the lung surface were counted. Each symbol represents an individual mouse; horizontal lines indicate the mean (***p < 0.001, one-way
ANOVA and Tukey’s post hoc test on day 21, unpaired t test on day 28).
(B) Representative lung photographs at the indicated time points after injection of B16F10 melanoma cells are shown.
(C) Kaplan-Meier plot of wild-type (n = 7) and Stat1-S727A (n = 7) mice intravenously injected with B16F10melanoma cells is illustrated. Log rank testing revealed
a significant difference in the onset of dyspnea (p = 0.027; MST wild-type = 31 days; MST Stat1-S727A = 40 days).
(D) Kaplan-Meier plot of wild-type (n = 8), Stat1-S727A (n = 8), and Stat1/ (n = 6) recipient animals inoculated intravenously with v-abl+ leukemic cells is
presented. Stat1-S727Amice succumb to leukemia with an increased latency (MST = 15 days) than wild-type (MST = 13 days) and Stat1/ (MST = 11.5 days)
animals. Log rank test was corrected with Bonferroni for multiple testing and revealed a significant difference between Stat1-S727A and wild-type (p = 0.0053)
and between Stat1-S727A and Stat1/ animals (p = 0.0023).
(E) Kaplan-Meier plot of Rag2//Stat1+/+ (n = 6) and Rag2//Stat1-S727A (n = 6) animals injected intravenously with v-abl+ leukemic cells is shown. Rag2/
/Stat1-S727Amice succumb to leukemia with increased latency (MST = 14 days) than Rag2//Stat1+/+ (MST = 12 days) animals. Log rank test was statistically
significant (p = 0.017).
See also Figure S3.metastasis formation, we transplanted 4T1 cells into Rag2/
and Rag2//Il2rg/ recipients. Twenty-eight days postinocu-
lation, Rag2//Il2rg/ mice showed increased metastatic
lung infiltrates compared to wild-type and Rag2/ animals
(Figure S4).
DISCUSSION
Our study reveals an inhibitory role of STAT1-S727 phosphoryla-
tion for NK cell cytotoxicity. STAT1-S727 is constitutively phos-
phorylated in unstimulated NK cells, where it modulates their
activity.
The transactivation domain of all STAT proteins except STAT2
harbors at least one conserved serine-phosphorylation site.
Experiments in Stat1-S727A-mutated NK cells show that
STAT1-S727 phosphorylation is a prerequisite for full IFN-g in-
duction, although it decreases granzyme B and perforin tran-
scription. Perforin function shows a pronounced gene-dosage(F) Knockdown of CDK8 with five hairpins in an immortalized Ink4a/ NK cell lin
(G) FACS-based cytotoxicity assay of immortalized NK cells transduced with a
presented. Symbols represent mean, and error bars indicate SEM of triplicates (
See also Figure S2.effect: Prf1+/ NK cells display reduced cytotoxicity (Lowin
et al., 1994). Higher perforin levels may thus lead to higher cyto-
toxicity, as we observed in Stat1-S727A NK cells. Cytotoxicity
might also be affected by additional mechanisms such as a
reduction of the inhibitory KLRG1 or an increase in expression
of partially activating NKG2A/C/E.
Several kinases phosphorylate STAT1-S727 upon stimulation,
depending on cell type and stimulus (Kovarik et al., 1999; Nair
et al., 2002; Deb et al., 2003; Bancerek et al., 2013). The transac-
tivation domain of STAT1 is also phosphorylated on S708, S744,
and S747. Phosphorylation on S708 has been attributed to IKKε
and is indispensable for antiviral IFN signaling (Tenoever et al.,
2007).
CDK8 has recently been identified as a major kinase in the
response to IFN signaling mediating STAT1-S727 phosphoryla-
tion (Bancerek et al., 2013). In fibroblasts and macrophages,
STAT1-S727 phosphorylation depends on stimulation by cyto-
kines. We now report an additional role for STAT1-S727e is shown. A random hairpin served as control.
random hairpin or a hairpin against CDK8 (#3) against YAC-1 target cells is
*p < 0.05, ***p < 0.001; unpaired t test).
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Figure 4. Stat1-S727AMice Are Resistant to
4T1 Breast Cancer Metastasis into Lungs
Wild-type (n = 11), Stat1-S727A (n = 12), and
Stat1/ (n = 6) animals received orthotopical
transplants of 4T1 breast cancer cells.
(A) Primary tumor volumes were measured weekly.
Symbols represent mean, and error bars indicate
SEM.
(B) Some recipients were sacrificed at day 27 (wild-
type n = 3, Stat1-S727A n = 6, Stat1/ n = 6) and
remaining recipients at day 31, then the primary
tumors were weighed. Bar graph depicts mean ±
SEM.
(C and D) Recipient mice were bled weekly, and (C)
WBCs and (D) MDSCs (GR1+CD11b+) were coun-
ted (*p < 0.05, **p < 0.01, ***p < 0.001; one-way
ANOVA and Tukey’s post hoc test on days 21 and
27; unpaired t test on day 31). Symbols represent
means, and error bars indicate SEM. n.s., not sig-
nificant.
(E and F) After termination of the experiment, (E)
lungs were weighed, and (F) the percentage (%) of
metastatic area in the lung was determined histo-
chemically (*p < 0.05, **p < 0.01, ***p < 0.001; one-
way ANOVA and Tukey’s post hoc test on day 27;
unpaired t test on day 31). Each symbol represents
an individual mouse; horizontal lines indicate the
mean.
(G) Representative H&E-stained lung sections of
Stat1/ animals at day 27 and wild-type and
Stat1-S727A animals at day 31 post trans-
plantation are shown.
See also Figure S4.phosphorylation, which is observed in NK cells even in the
absence of cytokines and with no concomitant tyrosine (Y701)
phosphorylation. We show that S727 phosphorylation exerts a
negative influence and show that a biological response is
restricted by STAT1-S727 phosphorylation independent of IFN
signaling. The Stat1-S727A mutant acts as a hypermorphic
rather than a hypomorphic allele of Stat1 in NK cells. Knockdown
of CDK8 verified its essential role for basal STAT1-S727 phos-
phorylation in NK cells and significantly enhanced cytotoxicity.
NK cells derived from Stat1-S727Amice are exceptionally cyto-
toxic and display signs of hyperactivity. Stat1-S727A mice are
less susceptible to B16F10 melanoma and v-abl+ leukemia and
are even resistant to 4T1 breast cancer metastasis. Hence, spe-
cific CDK8 kinase inhibitors may be useful in tumor therapy. A
combination of classical pharmacological target intervention
and novel immune cell-based strategies may be able to address
the complex nature of cancer immunology. The ability to442 Cell Reports 4, 437–444, August 15, 2013 ª2013 The Authors/
,
-
r
.
/
,
,
,
-generate NK cells primed to kill more effi-
ciently raises the hope of enhancing clin-
ical efficacy and outcome.
EXPERIMENTAL PROCEDURES
Mice
BALB/c and C57BL/6 wild-type(+/+), Stat1/
(Durbin et al., 1996), Stat1-S727A (Varinou et al.,
2003), Rag2/ (Shinkai et al., 1992), Rag2/Stat1-S727A, Rag2//Il2rg/ (Cao et al., 1995), Ifng/ (Dalton et al.
1993), and Ink4a/ (Serrano et al., 1996) mice were maintained under path
ogen-free conditions. The in vitro and B16F10 in vivo experiments were
performed with mice on C57BL/6 background. For v-abl+ and 4T1 tumo
models, mice on BALB/c background were used. All experiments were carried
out with gender- and age-matched 6- to 12-week-old mice, were approved by
the institutional ethics committee, and conform to Austrian laws (license
66.009/0019-II/10b/2010 14.1.10).
Inhibitor Studies and shRNA Knockdown
Web-based inquiries, e.g., Group-based Prediction System (GPS; http://gps
biocuckoo.org/) and KinasePhos 2.0 (http://kinasephos2.mbc.nctu.edu.tw
index.html), were performed. For inhibitor studies, LAK cells were deprived
of IL-2 for 3 hr prior to 4 hr treatment with 30 mM DMSO (Carl Roth)
100 ng/ml anisomycin (Sigma-Aldrich), 5 mM roscovitine (Calbiochem)
0.5 mM flavopiridol (Sigma-Aldrich), 1 mM BIRB 0796 (Bo¨hringer Ingelheim)
or 25 mM SB 203580 (Sigma-Aldrich).
For shRNA-mediated knockdown of CDK8, five pGIPZ clones (RMM4532
NM_001260) and two TRC clones (TRCN0000023107 and TRCN
0000023268) were obtained from Open Biosystems. The best knockdown
efficiency was shown by clone 3 for pGIPZ (V2LMM_192695) and clone
TRCN0000023268 for TRC. A clone containing a validated nonsilencing
shRNA (RHS4346 for pGIPZ and RHS4080 for TRC) served as control. VSV-
G-pseudotyped lentiviruses were produced as described previously (Hoer-
mann et al., 2011). Recombinant lentiviruses were produced in HEK293T cells
with pGIPZ vectors and plasmids encoding GAG-POL and VSV-G. NK cells
were transduced by spin infection (800 3 g, 90 min, 32C) in the presence of
7 mg/ml Polybrene (Sigma-Aldrich) and selected with 2 mg/ml puromycin
(Invivogen/Eubio) for 5 days.
In Vitro Cytotoxicity Assay
Standard 4 hr [51Cr]-release assays and flow cytometry-based cytotoxicity
assays (Zebedin et al., 2008; Schuster et al., 2011) are described in detail in
the Extended Experimental Procedures.
B16F10 Tumor Model
Mice were injected via tail vein with 53 104 B16F10melanoma cells and sacri-
ficed after 7, 14, 21, or 28 days (time course) or at the first sign of dyspnea
(Kaplan-Meier). Stat1/ mice were included only until day 21. Lungs were
removed, weighed, and captured on camera, and the visible tumor nodules
on their surface were counted.
Leukemia Model
Single-cell suspensions from BALB/c bone marrow were infected with
A-MuLV retrovirus in the presence of 7 mg/ml Polybrene (Sigma-Aldrich) and
10 ng/ml rmIL-7 (PeproTech) to establish stable cell lines. After intravenous
injection of 105 v-abl+ leukemic cells, mice were checked daily for the onset
of leukemia and sacrificed at the first sign of disease. They were analyzed
for spleen and liver weight and the presence of leukemic cells
(CD19+CD43+B220+) in bone marrow, spleen, and blood.
4T1 Tumor Model
A total of 5 3 105 tumor cells/30 ml PBS was injected in the fat pad of the fifth
pair of mammary glands of sedated mice. Once a week, tumor volumes were
measured (tumor volume = (width2 3 length)/2) and WBCs determined in an
animal blood counter (Scil Animal Care). GR1+CD11b+ MDSCs in the blood
were assessed via flow cytometry. At the indicated time points, lungs were
excised, paraformaldehyde fixed, and paraffin embedded, and six to ten
sections (3 mm) were stained with hematoxylin and eosin (H&E, Microm HMS
740 Robot Stainer; Thermo Scientific) and scanned with a Zeiss MIRAX scan-
ner. The percentage of metastatic lung area was quantified by Definiens Ana-
lyst software.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 5.00 forWin-
dows (GraphPad Software; http://www.graphpad.com). Where ANOVA
showed a statistical difference, Tukey’s multiple comparison testing was
applied. Comparison of more than two survival curves was made by the Bon-
ferroni correction of log rank tests. The a level for all tests was set to 0.05, and p
values were two tailed. The significance level is indicated for each experiment
(in general: *p < 0.05; **p < 0.01; ***p < 0.001).
For further details, see the Extended Experimental Procedures and
Table S2.
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Supplemental Information includes Extended Results, Extended Experimental
Procedures, four figures, and two tables and can be found with this article
online at http://dx.doi.org/10.1016/j.celrep.2013.07.012.
ACKNOWLEDGMENTS
We are indebted to S. Fajmann, S. Wienerroither, M. Parrini, K. Schelch, M.
Mair, M. Prchal-Murphy, and B. Strobl for support and scientific input and G.
Tebb for careful reading and revision of the manuscript. We are grateful tothe mouse facility. The work was supported by the Austrian Academy of Sci-
ence DOC-fFORTE fellowship (to E.M.P.; http://stipendien.oeaw.ac.at/en),
the Austrian Science Fund FWF grant SFB F28 (to M.M., T.D., and V.S.;
http://www.fwf.ac.at/en/projects/sfb.html), and the GEN-AU program ‘‘Aus-
tromouse’’ of the Austrian Federal Ministry of Science and Research (to
M.M.; http://www.gen-au.at/projekt.jsp?projektId=110&lang=en).
Received: August 9, 2012
Revised: February 6, 2013
Accepted: July 11, 2013
Published: August 8, 2013
WEB RESOURCES
The URLs for data presented herein are as follows:
Austrian Academy of Science DOC-fFORTE fellowship, http://stipendien.
oeaw.ac.at/en
Austrian Science Fund FWF grant SFB F28, http://www.fwf.ac.at/en/projects/
sfb.html
GEN-AU program ‘‘Austromouse’’ of the Austrian Federal Ministry of Science
and Research, http://www.gen-au.at/projekt.jsp?projektId=110&lang=en
GPS, http://gps.biocuckoo.org/
GraphPad Software, http://www.graphpad.com
KinasePhos 2.0, http://kinasephos2.mbc.nctu.edu.tw/index.htmlREFERENCES
Bancerek, J., Poss, Z.C., Steinparzer, I., Sedlyarov, V., Pfaffenwimmer, T.,
Mikulic, I., Do¨lken, L., Strobl, B., Mu¨ller, M., Taatjes, D.J., and Kovarik, P.
(2013). CDK8 kinase phosphorylates transcription factor STAT1 to selectively
regulate the interferon response. Immunity 38, 250–262.
Bromberg, J.F., Horvath, C.M., Wen, Z., Schreiber, R.D., and Darnell, J.E., Jr.
(1996). Transcriptionally active Stat1 is required for the antiproliferative effects
of both interferon alpha and interferon gamma. Proc. Natl. Acad. Sci. USA 93,
7673–7678.
Cao, X., Shores, E.W., Hu-Li, J., Anver, M.R., Kelsall, B.L., Russell, S.M.,
Drago, J., Noguchi, M., Grinberg, A., Bloom, E.T., et al. (1995). Defective
lymphoid development in mice lacking expression of the common cytokine
receptor gamma chain. Immunity 2, 223–238.
Dalton, D.K., Pitts-Meek, S., Keshav, S., Figari, I.S., Bradley, A., and Stewart,
T.A. (1993). Multiple defects of immune cell function in mice with disrupted
interferon-gamma genes. Science 259, 1739–1742.
Davis, M.I., Hunt, J.P., Herrgard, S., Ciceri, P., Wodicka, L.M., Pallares, G.,
Hocker, M., Treiber, D.K., and Zarrinkar, P.P. (2011). Comprehensive analysis
of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046–1051.
Deb, D.K., Sassano, A., Lekmine, F., Majchrzak, B., Verma, A., Kambhampati,
S., Uddin, S., Rahman, A., Fish, E.N., and Platanias, L.C. (2003). Activation of
protein kinase C delta by IFN-gamma. J. Immunol. 171, 267–273.
Durbin, J.E., Hackenmiller, R., Simon, M.C., and Levy, D.E. (1996). Targeted
disruption of the mouse Stat1 gene results in compromised innate immunity
to viral disease. Cell 84, 443–450.
Hoermann, G., Cerny-Reiterer, S., Perne´, A., Klauser, M., Hoetzenecker, K.,
Klein, K., Mu¨llauer, L., Gro¨ger, M., Nijman, S.M.B., Klepetko, W., et al.
(2011). Identification of oncostatin M as a STAT5-dependent mediator of
bone marrow remodeling in KIT D816V-positive systemic mastocytosis. Am.
J. Pathol. 178, 2344–2356.
Horvath, C.M., and Darnell, J.E., Jr. (1996). The antiviral state induced by alpha
interferon and gamma interferon requires transcriptionally active Stat1 protein.
J. Virol. 70, 647–650.
Kaplan, D.H., Shankaran, V., Dighe, A.S., Stockert, E., Aguet, M., Old, L.J., and
Schreiber, R.D. (1998). Demonstration of an interferon gamma-dependent
tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci.
USA 95, 7556–7561.Cell Reports 4, 437–444, August 15, 2013 ª2013 The Authors 443
Klover, P.J., Muller, W.J., Robinson, G.W., Pfeiffer, R.M., Yamaji, D., and
Hennighausen, L. (2010). Loss of STAT1 from mouse mammary epithe-
lium results in an increased Neu-induced tumor burden. Neoplasia 12,
899–905.
Koromilas, A.E., and Sexl, V. (2013). The tumor suppressor function of STAT1
in breast cancer. JAKSTAT 2, 1–5.
Kovacic, B., Stoiber, D., Moriggl, R., Weisz, E., Ott, R.G., Kreibich, R., Levy,
D.E., Beug, H., Freissmuth, M., and Sexl, V. (2006). STAT1 acts as a tumor pro-
moter for leukemia development. Cancer Cell 10, 77–87.
Kovarik, P., Stoiber, D., Eyers, P.A., Menghini, R., Neininger, A., Gaestel, M.,
Cohen, P., and Decker, T. (1999). Stress-induced phosphorylation of STAT1
at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma
uses a different signaling pathway. Proc. Natl. Acad. Sci. USA 96, 13956–
13961.
Lee, C.K., Rao, D.T., Gertner, R., Gimeno, R., Frey, A.B., and Levy, D.E. (2000).
Distinct requirements for IFNs and STAT1 in NK cell function. J. Immunol. 165,
3571–3577.
Lodolce, J.P., Boone, D.L., Chai, S., Swain, R.E., Dassopoulos, T., Trettin, S.,
andMa, A. (1998). IL-15 receptormaintains lymphoid homeostasis by support-
ing lymphocyte homing and proliferation. Immunity 9, 669–676.
Lowin, B., Beermann, F., Schmidt, A., and Tschopp, J. (1994). A null mutation
in the perforin gene impairs cytolytic T lymphocyte- and natural killer cell-medi-
ated cytotoxicity. Proc. Natl. Acad. Sci. USA 91, 11571–11575.
Lucas, M., Schachterle, W., Oberle, K., Aichele, P., and Diefenbach, A. (2007).
Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Im-
munity 26, 503–517.
Nair, J.S., DaFonseca, C.J., Tjernberg, A., Sun, W., Darnell, J.E., Jr., Chait,
B.T., and Zhang, J.J. (2002). Requirement of Ca2+ and CaMKII for Stat1
Ser-727 phosphorylation in response to IFN-gamma. Proc. Natl. Acad. Sci.
USA 99, 5971–5976.
Nguyen, K.B., Salazar-Mather, T.P., Dalod, M.Y., Van Deusen, J.B., Wei, X.Q.,
Liew, F.Y., Caligiuri, M.A., Durbin, J.E., and Biron, C.A. (2002). Coordinated
and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell
responses to viral infection. J. Immunol. 169, 4279–4287.
Pilz, A., Kratky, W., Stockinger, S., Simma, O., Kalinke, U., Lingnau, K., von
Gabain, A., Stoiber, D., Sexl, V., Kolbe, T., et al. (2009). Dendritic cells require
STAT-1 phosphorylated at its transactivating domain for the induction of pep-
tide-specific CTL. J. Immunol. 183, 2286–2293.
Robbins, S.H., Tessmer, M.S., Van Kaer, L., and Brossay, L. (2005). Direct ef-
fects of T-bet and MHC class I expression, but not STAT1, on peripheral NK
cell maturation. Eur. J. Immunol. 35, 757–765.
Sadzak, I., Schiff, M., Gattermeier, I., Glinitzer, R., Sauer, I., Saalmu¨ller, A.,
Yang, E., Schaljo, B., and Kovarik, P. (2008). Recruitment of Stat1 to chromatin
is required for interferon-induced serine phosphorylation of Stat1 transactiva-
tion domain. Proc. Natl. Acad. Sci. USA 105, 8944–8949.
Schneckenleithner, C., Bago-Horvath, Z., Dolznig, H., Neugebauer, N., Koll-
mann, K., Kolbe, T., Decker, T., Kerjaschki, D., Wagner, K.-U., Mu¨ller, M.,444 Cell Reports 4, 437–444, August 15, 2013 ª2013 The Authorset al. (2011). Putting the brakes on mammary tumorigenesis: loss of STAT1
predisposes to intraepithelial neoplasias. Oncotarget 2, 1043–1054.
Schroder, K., Spille, M., Pilz, A., Lattin, J., Bode, K.A., Irvine, K.M., Burrows,
A.D., Ravasi, T., Weighardt, H., Stacey, K.J., et al. (2007). Differential effects
of CpG DNA on IFN-beta induction and STAT1 activation in murine macro-
phages versus dendritic cells: alternatively activated STAT1 negatively regu-
lates TLR signaling in macrophages. J. Immunol. 179, 3495–3503.
Schuster, C., Berger, A., Hoelzl, M.A., Putz, E.M., Frenzel, A., Simma, O., Mor-
itz, N., Hoelbl, A., Kovacic, B., Freissmuth, M., et al. (2011). The cooperating
mutation or ‘‘second hit’’ determines the immunologic visibility toward MYC-
induced murine lymphomas. Blood 118, 4635–4645.
Serrano, M., Lee, H., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R.A.
(1996). Role of the INK4a locus in tumor suppression and cell mortality. Cell 85,
27–37.
Shinkai, Y., Rathbun, G., Lam, K.P., Oltz, E.M., Stewart, V., Mendelsohn, M.,
Charron, J., Datta, M., Young, F., Stall, A.M., et al. (1992). RAG-2-deficient
mice lack mature lymphocytes owing to inability to initiate V(D)J rearrange-
ment. Cell 68, 855–867.
Stark, G.R.R., andDarnell, J.E.E., Jr. (2012). The JAK-STAT pathway at twenty.
Immunity 36, 503–514.
Stoiber, D., Kovacic, B., Schuster, C., Schellack, C., Karaghiosoff, M., Krei-
bich, R., Weisz, E., Artwohl, M., Kleine, O.C., Mu¨ller, M., et al. (2004). TYK2
is a key regulator of the surveillance of B lymphoid tumors. J. Clin. Invest.
114, 1650–1658.
Tenoever, B.R., Ng, S.L., Chua, M.A., McWhirter, S.M., Garcı´a-Sastre, A., and
Maniatis, T. (2007). Multiple functions of the IKK-related kinase IKKepsilon in
interferon-mediated antiviral immunity. Science 315, 1274–1278.
Varinou, L., Ramsauer, K., Karaghiosoff, M., Kolbe, T., Pfeffer, K., Mu¨ller, M.,
and Decker, T. (2003). Phosphorylation of the Stat1 transactivation domain
is required for full-fledged IFN-gamma-dependent innate immunity. Immunity
19, 793–802.
Vivier, E., Raulet, D.H., Moretta, A., Caligiuri, M.A., Zitvogel, L., Lanier, L.L.,
Yokoyama, W.M., and Ugolini, S. (2011). Innate or adaptive immunity? The
example of natural killer cells. Science 331, 44–49.
Wang, P., Gu, Y., Zhang, Q., Han, Y., Hou, J., Lin, L., Wu, C., Bao, Y., Su, X.,
Jiang, M., et al. (2012). Identification of resting and type I IFN-activated human
NK cell miRNomes revealsmicroRNA-378 andmicroRNA-30e as negative reg-
ulators of NK cell cytotoxicity. J. Immunol. 189, 211–221.
Watford, W.T., Hissong, B.D., Bream, J.H., Kanno, Y., Muul, L., and O’Shea,
J.J. (2004). Signaling by IL-12 and IL-23 and the immunoregulatory roles of
STAT4. Immunol. Rev. 202, 139–156.
Wen, Z., Zhong, Z., and Darnell, J.E., Jr. (1995). Maximal activation of tran-
scription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation.
Cell 82, 241–250.
Zebedin, E., Simma, O., Schuster, C., Putz, E.M., Fajmann, S., Warsch, W.,
Eckelhart, E., Stoiber, D., Weisz, E., Schmid, J.A., et al. (2008). Leukemic chal-
lenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveil-
lance. Blood 112, 4655–4664.
